Omnisystem

At a glance

Omnisystem filed 41 disclosures in the last 12 months, including 9 insider, 5 5% holder and 3 buyback. The most recent key filing was on Oct 20: A major holder's stake rose from 37.17% to 37.17% (share consolidation/split).

Revenue for 2025 was ₩99.1B, down 9.2% on 2024. Operating margin was 1% against 5.5% a year earlier. Debt was 18% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩42.6B and operating loss of ₩212.6M.

The 2025 annual report lists 247 employees with an average tenure of 7.3 years and average pay of ₩47.8M, #1553 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩172.1M each on average. It paid no cash dividend for 2025. (주)바이오스마트 and related parties held 23.41% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 37.17% on Oct 20.

From the 2025 annual report

Staff: 247 (166 men, 81 women), of whom 19 on fixed-term contracts. Total pay for the year: ₩11.8B. Directors and auditors: 5, paid ₩860.5M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)바이오스마트 holds 23.36%; with 2 related parties the group holds 23.41% of common shares at year end (from 22.64% at the start of the year).

Auditor: 대성회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports